Generic · Tablet · Updated Nov 11, 2026
Deferasirox 360 mg tablet price what pharmacies pay, and what you should
Is my price fair?
Check the price you were quoted
Type what the pharmacy asked for deferasirox 360 mg tablet and see the markup over what they pay.
A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.
Deferasirox 360 mg price history
What pharmacies pay for 30 tablets, weekly- Now
- $33.58
- 52-week low
- $33.58
- 52-week high
- $49.30
- A year ago
- $38.02
Why the price changed
| Effective | Before | After | Change | Reason |
|---|---|---|---|---|
| Oct 21, 2026 | $1.25 | $1.12 | -10.3% | pharmacies' invoice prices changed (survey) |
| Sep 23, 2026 | $1.34 | $1.25 | -6.9% | pharmacies' invoice prices changed (survey) |
| Aug 19, 2026 | $1.47 | $1.34 | -8.9% | pharmacies' invoice prices changed (survey) |
| Jul 22, 2026 | $1.50 | $1.47 | -1.7% | pharmacies' invoice prices changed (survey) |
| Jun 17, 2026 | $1.54 | $1.50 | -3.2% | pharmacies' invoice prices changed (survey) |
| May 20, 2026 | $1.57 | $1.54 | -1.4% | pharmacies' invoice prices changed (survey) |
| Apr 22, 2026 | $1.64 | $1.57 | -4.7% | pharmacies' invoice prices changed (survey) |
| Mar 18, 2026 | $1.27 | $1.64 | +29.6% | pharmacies' invoice prices changed (survey) |
Prices per tablet. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.
What people paid for deferasirox 360 mg tablet
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
9 companies sell deferasirox 360 mg tablet under 9 package codes (NDCs). Pharmacies pay the same per tablet whichever maker they buy from - the national average is set for the generic as a group.
| Maker | Package codes | Per unit |
|---|---|---|
| Alembic Pharmaceuticals Inc. | 62332-412-30 | $1.12 |
| Ascend Laboratories, LLC | 67877-554-30 | $1.12 |
| Aurobindo Pharma Limited | 59651-412-30 | $1.12 |
| Camber Pharmaceuticals, Inc. | 31722-013-30 | $1.12 |
| Dr. Reddy's Laboratories Inc | 43598-851-30 | $1.12 |
| NorthStar Rx LLC | 72603-233-01 | $1.12 |
| Xiromed, LLC | 70700-271-30 | $1.12 |
| Zydus Pharmaceuticals USA Inc. | 70710-1277-3 | $1.12 |
| AvKARE | 73190-052-30 | - |
All 9 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Questions to ask your pharmacist
- "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
- "Is a 90-day supply cheaper per tablet?" Dispensing fees are charged per fill, so fewer fills often cost less.
- "Do you match other pharmacies or accept discount cards?" Many do, if you ask.
These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.
Other deferasirox strengths and forms
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 180 mg tablet | Not priced this week | |||
| 500 mg tablet for oral suspension | $5.85 | $175.57 / 30 tablets | ||
Official label & what changed
These highlights do not include all the information needed to use DEFERASIROX TABLETS safely and effectively. See full prescribing information for DEFERASIROX TABLETS. DEFERASIROX tablets, for oral use Initial U.S. Approval: 2005
WARNING: RENAL FAILURE, HEPATIC FAILURE, AND GASRTOINTESTINAL HEMORRHAGE
Renal Failure
Deferasirox can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders.
Evaluate baseline renal function prior to starting or increasing deferasirox dosing in all patients. Deferasirox is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m2. Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, then at least monthly. Reduce the starting dose in patients with preexisting renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of renal impairment, including use of concomitant nephrotoxic drugs, and pediatric patients with volume depletion or overchelation [see Dosage and Administration (2.1, 2.4, 2.5), Warnings and Precautions (5.1), Adverse Reactions (6.1, 6.2)].
Hepatic Failure
Deferasirox can cause hepatic injury including hepatic failure and death.
Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter.
Avoid use of deferasirox in patients with severe (Child-Pugh C) hepatic impairment and reduce the dose in patients with moderate (Child-Pugh B) hepatic impairment [see Dosage and Administration (2.4), Warnings and Precautions (5.2)].
Gastrointestinal Hemorrhage
Deferasirox can cause gastrointestinal (GI) hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts.
Monitor patients and discontinue deferasirox for suspected GI ulceration or hemorrhage [see Warnings and Precautions (5.3)].
WARNING: RENAL FAILURE, HEPATIC FAILURE, AND GASTROINTESTINAL HEMORRHAGE
See full prescribing information for complete boxed warning.
Deferasirox may cause serious and fatal:
acute kidney injury, including acute renal failure requiring dialysis and renal tubular toxicity including Fanconi syndrome (5.1)
hepatic toxicity, including failure (5.2)
gastrointestinal hemorrhage (5.3)
Deferasirox therapy requires close patient monitoring, including laboratory tests of renal and hepatic function. (5)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about deferasirox 360 mg tablet
How much does deferasirox 360 mg tablet cost without insurance?
Pharmacies pay about $33.58 for 30 tablets ($1.12 per tablet) as of November 11, 2026. A fair cash price is about $49.12: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $48.62 including shipping.
Is my price for deferasirox 360 mg tablet fair?
Compare it with the fair cash price of $49.12 for 30 tablets. Up to about $61.40 is fair; above $98.24 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.
Is deferasirox 360 mg tablet getting more expensive?
Over the last four weeks the price pharmacies pay fell 10.3%. Over a year it fell 11.7%. See the 52-week chart.
Who makes deferasirox 360 mg tablet?
9 companies: Alembic Pharmaceuticals Inc., Ascend Laboratories, LLC, Aurobindo Pharma Limited, Camber Pharmaceuticals, Inc., Dr. Reddy's Laboratories Inc, NorthStar Rx LLC, Xiromed, LLC, Zydus Pharmaceuticals USA Inc., AvKARE. See every package code.
Is deferasirox in shortage?
No shortage is reported right now. We check every day.
Has deferasirox been recalled?
1 recall on record, 1 ongoing. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about deferasirox 360 mg tablet
No comments yet. Questions, tips, what worked for you - start the conversation.